On Thursday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.71 which represents a decrease of $-0.02 or -2.74% from the prior close of $0.73. The stock opened at $0.74 and touched a low ...
Hosted on MSN1mon
Ocugen reports positive data for OCU400, OCU410Ocugen released the data as part of its recent Clinical Showcase presentation, which is also posted on its website, according to a statement.
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410 ...
On Tuesday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.73 which represents a decrease of $-0.02 or -2.67% from the prior close of $0.75. The stock opened at $0.75 and touched a low of ...
Ocugen, Inc. announced that the Data and Safety Monitoring Board has approved the continuation of the second phase of the Phase 1/2 OCU410 ArMaDa clinical trial for treating geographic atrophy (GA ...
US biotechs Ocugen and Histogenics have announced plans to merge, creating a specialist in drugs and gene therapies for ocular diseases. Shares in Nasdaq-listed Histogenics almost tripled in the ...
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback